Skip to main content
. Author manuscript; available in PMC: 2022 Aug 16.
Published in final edited form as: Neuropharmacology. 2018 Jun 21;138:304–314. doi: 10.1016/j.neuropharm.2018.06.024

Fig. 5.

Fig. 5.

Effects of co-administration of D1R Agonist SKF38393 and/or D3R Agonist PD128907 on ALO AIMs (Fig. 5A) and striatal pERK1/2 expression (Fig. 5B). In a between-subjects design rats were treated with either vehicle (SKF(0) + PD (0) mg/kg), D1R agonist SKF38393 (SKF; 0.3 mg/kg), D3R agonist PD128907 (PD; 0.1 mg/kg), or both (SKF(0.3) + PD (0.1) mg/kg).Non-responders (NR) were also treated with both (SKF(0.3). PD (0.1) mg/kg). Rats were rated for ALO AIMs for 30 min post-injection. AIMs time course and ALO sums are expressed as medians (ALO +median absolute difference; M.A.D Significant AIMs differences were determined by non-parametric Kruskal Wallis ANOVAs with Mann Whitney U Pairs post-hoc tests as necessary. After 30 min, rats were sacrificed, dorsal striatum was collected and subsequently underwent whole cell Western Blot procedures. The ratio of pERK1/2 to total ERK1/2 is shown. Significant differences were detected with a one-way ANOVA and LSD post-hoc tests as appropriate (@p < .05 Syn vs. vehicle, *p < .05 Syn vs. ALL, &p < .05 Syn vs. SKF, ~p < .05 Syn vs. NR).